Wheeler Bio's $31M In Financing To Support Clinical Drug Substance Mfg. Facility
To build a disruptive CDMO model aimed at changing the paradigm for the gene-to-IND supply chain.
Source: contractpharma.com
Stay updated with breaking news from Ambr Microbioreactors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
To build a disruptive CDMO model aimed at changing the paradigm for the gene-to-IND supply chain.